On October 28, Lilly said in a statement that it had obtained the approval of the Hong Kong SAR government to sell its Tirzepatide injection (trade name: Mounjaro) through a device called Kwikpen (pre filled injection pen) for long-term weight management and type 2 diabetes. Lilly is expected to start selling this weight loss medication in Hong Kong as early as the end of this year. (Bloomberg)